nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftibuten—Nephropathy toxic—Teniposide—lymphatic system cancer	0.0284	0.0284	CcSEcCtD
Ceftibuten—Digestion impaired—Fludarabine—lymphatic system cancer	0.0215	0.0215	CcSEcCtD
Ceftibuten—Nephropathy toxic—Bleomycin—lymphatic system cancer	0.0183	0.0183	CcSEcCtD
Ceftibuten—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Ceftibuten—Nephropathy toxic—Carmustine—lymphatic system cancer	0.016	0.016	CcSEcCtD
Ceftibuten—Nephropathy toxic—Mitoxantrone—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Ceftibuten—Aphasia—Carmustine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Ceftibuten—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Ceftibuten—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Ceftibuten—Jaundice—Mechlorethamine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Ceftibuten—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Ceftibuten—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Ceftibuten—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Ceftibuten—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Ceftibuten—Pancytopenia—Teniposide—lymphatic system cancer	0.00973	0.00973	CcSEcCtD
Ceftibuten—Dehydration—Fludarabine—lymphatic system cancer	0.00969	0.00969	CcSEcCtD
Ceftibuten—Neutropenia—Teniposide—lymphatic system cancer	0.00958	0.00958	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00938	0.00938	CcSEcCtD
Ceftibuten—Candida infection—Carmustine—lymphatic system cancer	0.00877	0.00877	CcSEcCtD
Ceftibuten—Pancytopenia—Fludarabine—lymphatic system cancer	0.00855	0.00855	CcSEcCtD
Ceftibuten—Dysuria—Fludarabine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Ceftibuten—Neutropenia—Fludarabine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Ceftibuten—Haemoglobin—Teniposide—lymphatic system cancer	0.00824	0.00824	CcSEcCtD
Ceftibuten—Haemorrhage—Teniposide—lymphatic system cancer	0.0082	0.0082	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00796	0.00796	CcSEcCtD
Ceftibuten—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0079	0.0079	CcSEcCtD
Ceftibuten—Renal failure—Fludarabine—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Ceftibuten—Haematuria—Fludarabine—lymphatic system cancer	0.00765	0.00765	CcSEcCtD
Ceftibuten—Anorexia—Mechlorethamine—lymphatic system cancer	0.00753	0.00753	CcSEcCtD
Ceftibuten—Chills—Teniposide—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Ceftibuten—Haemoglobin—Fludarabine—lymphatic system cancer	0.00724	0.00724	CcSEcCtD
Ceftibuten—Haemorrhage—Fludarabine—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Ceftibuten—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Ceftibuten—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00681	0.00681	CcSEcCtD
Ceftibuten—Agitation—Teniposide—lymphatic system cancer	0.00656	0.00656	CcSEcCtD
Ceftibuten—Aphasia—Methotrexate—lymphatic system cancer	0.00656	0.00656	CcSEcCtD
Ceftibuten—Chills—Fludarabine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Ceftibuten—Pancytopenia—Bleomycin—lymphatic system cancer	0.00627	0.00627	CcSEcCtD
Ceftibuten—Dehydration—Vincristine—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Ceftibuten—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Ceftibuten—Agitation—Fludarabine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Ceftibuten—Dehydration—Mitoxantrone—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Ceftibuten—Haematuria—Bleomycin—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Ceftibuten—Pruritus—Mechlorethamine—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Ceftibuten—Anorexia—Teniposide—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Ceftibuten—Pancytopenia—Carmustine—lymphatic system cancer	0.00547	0.00547	CcSEcCtD
Ceftibuten—Convulsion—Fludarabine—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Ceftibuten—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Ceftibuten—Neutropenia—Carmustine—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Ceftibuten—Haemoglobin—Bleomycin—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Ceftibuten—Haemorrhage—Bleomycin—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Ceftibuten—Pancytopenia—Vincristine—lymphatic system cancer	0.00522	0.00522	CcSEcCtD
Ceftibuten—Dyspnoea—Teniposide—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Ceftibuten—Dysuria—Vincristine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Ceftibuten—Neutropenia—Vincristine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Ceftibuten—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Ceftibuten—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Ceftibuten—Decreased appetite—Teniposide—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Ceftibuten—Renal failure—Carmustine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Ceftibuten—Vomiting—Mechlorethamine—lymphatic system cancer	0.00502	0.00502	CcSEcCtD
Ceftibuten—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Ceftibuten—Rash—Mechlorethamine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Ceftibuten—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Ceftibuten—Anorexia—Fludarabine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Ceftibuten—Chills—Bleomycin—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Ceftibuten—Renal failure—Mitoxantrone—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Ceftibuten—Nausea—Mechlorethamine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Ceftibuten—Jaundice—Mitoxantrone—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Ceftibuten—Haemoglobin—Carmustine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Ceftibuten—Urticaria—Teniposide—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Ceftibuten—Haemorrhage—Carmustine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Ceftibuten—Body temperature increased—Teniposide—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ceftibuten—Abdominal pain—Teniposide—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ceftibuten—Paraesthesia—Fludarabine—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Ceftibuten—Dyspnoea—Fludarabine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Ceftibuten—Haematuria—Mitoxantrone—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Ceftibuten—Dyspepsia—Fludarabine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Ceftibuten—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Ceftibuten—Decreased appetite—Fludarabine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Ceftibuten—Fatigue—Fludarabine—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Ceftibuten—Constipation—Fludarabine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Ceftibuten—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Ceftibuten—Hypersensitivity—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Ceftibuten—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Ceftibuten—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Ceftibuten—Asthenia—Teniposide—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Ceftibuten—Melaena—Methotrexate—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Ceftibuten—Pruritus—Teniposide—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Ceftibuten—Body temperature increased—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Ceftibuten—Vaginal infection—Methotrexate—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Ceftibuten—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Ceftibuten—Diarrhoea—Teniposide—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Ceftibuten—Chills—Mitoxantrone—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Ceftibuten—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Ceftibuten—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Ceftibuten—Vomiting—Teniposide—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Ceftibuten—Agitation—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Ceftibuten—Asthenia—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Ceftibuten—Rash—Teniposide—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Ceftibuten—Dermatitis—Teniposide—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Ceftibuten—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Ceftibuten—Headache—Teniposide—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Ceftibuten—Pruritus—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Ceftibuten—Anorexia—Bleomycin—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Ceftibuten—Agitation—Vincristine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Ceftibuten—Diarrhoea—Fludarabine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Ceftibuten—Convulsion—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Ceftibuten—Nausea—Teniposide—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Ceftibuten—Paraesthesia—Bleomycin—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Ceftibuten—Dyspnoea—Bleomycin—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Ceftibuten—Convulsion—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Ceftibuten—Decreased appetite—Bleomycin—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Ceftibuten—Vomiting—Fludarabine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Ceftibuten—Convulsion—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Ceftibuten—Rash—Fludarabine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Ceftibuten—Dermatitis—Fludarabine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Ceftibuten—Headache—Fludarabine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Ceftibuten—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Ceftibuten—Anorexia—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Ceftibuten—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Ceftibuten—Nausea—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Ceftibuten—Urticaria—Bleomycin—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Ceftibuten—Anorexia—Vincristine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Ceftibuten—Body temperature increased—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Ceftibuten—Insomnia—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Ceftibuten—Irritability—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Ceftibuten—Paraesthesia—Carmustine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Ceftibuten—Dyspnoea—Carmustine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Ceftibuten—Somnolence—Carmustine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Ceftibuten—Anorexia—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Ceftibuten—Decreased appetite—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Ceftibuten—Insomnia—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Ceftibuten—Paraesthesia—Vincristine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Ceftibuten—Constipation—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Ceftibuten—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Ceftibuten—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Ceftibuten—Decreased appetite—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Ceftibuten—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Ceftibuten—Somnolence—Mitoxantrone—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Ceftibuten—Fatigue—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Ceftibuten—Asthenia—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Ceftibuten—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ceftibuten—Constipation—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Ceftibuten—Pruritus—Bleomycin—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Ceftibuten—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Ceftibuten—Fatigue—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Ceftibuten—Constipation—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Ceftibuten—Body temperature increased—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Ceftibuten—Abdominal pain—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Ceftibuten—Pancytopenia—Methotrexate—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Ceftibuten—Dysuria—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Ceftibuten—Neutropenia—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Ceftibuten—Abdominal pain—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Ceftibuten—Body temperature increased—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Ceftibuten—Urticaria—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Ceftibuten—Hypersensitivity—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Ceftibuten—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Ceftibuten—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Ceftibuten—Vomiting—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Ceftibuten—Rash—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Ceftibuten—Dermatitis—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Ceftibuten—Asthenia—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Ceftibuten—Renal failure—Methotrexate—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Ceftibuten—Hypersensitivity—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Ceftibuten—Haematuria—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Ceftibuten—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Ceftibuten—Asthenia—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Ceftibuten—Diarrhoea—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Ceftibuten—Nausea—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Ceftibuten—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Ceftibuten—Asthenia—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Ceftibuten—Dizziness—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Ceftibuten—Haemoglobin—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Ceftibuten—Diarrhoea—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ceftibuten—Haemorrhage—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ceftibuten—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Ceftibuten—Vomiting—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Ceftibuten—Dizziness—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Ceftibuten—Rash—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Ceftibuten—Dermatitis—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Ceftibuten—Headache—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Ceftibuten—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Ceftibuten—Vomiting—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Ceftibuten—Rash—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ceftibuten—Dermatitis—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ceftibuten—Headache—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ceftibuten—Nausea—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Ceftibuten—Vomiting—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Ceftibuten—Rash—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Ceftibuten—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Ceftibuten—Chills—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Ceftibuten—Headache—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Ceftibuten—Nausea—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Ceftibuten—Dysgeusia—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Ceftibuten—Nausea—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Ceftibuten—Convulsion—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ceftibuten—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Ceftibuten—Anorexia—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Ceftibuten—Insomnia—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ceftibuten—Paraesthesia—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Ceftibuten—Dyspnoea—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Ceftibuten—Somnolence—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Ceftibuten—Dyspepsia—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ceftibuten—Decreased appetite—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ceftibuten—Fatigue—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ceftibuten—Urticaria—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ceftibuten—Abdominal pain—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ceftibuten—Body temperature increased—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ceftibuten—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ceftibuten—Asthenia—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Ceftibuten—Pruritus—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ceftibuten—Diarrhoea—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Ceftibuten—Dizziness—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ceftibuten—Vomiting—Methotrexate—lymphatic system cancer	0.000965	0.000965	CcSEcCtD
Ceftibuten—Rash—Methotrexate—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Ceftibuten—Dermatitis—Methotrexate—lymphatic system cancer	0.000956	0.000956	CcSEcCtD
Ceftibuten—Headache—Methotrexate—lymphatic system cancer	0.000951	0.000951	CcSEcCtD
Ceftibuten—Nausea—Methotrexate—lymphatic system cancer	0.000901	0.000901	CcSEcCtD
